|
KMID : 1151620180030020064
|
|
Journal of Retina
2018 Volume.3 No. 2 p.64 ~ p.70
|
|
|
Long-Term Visual Outcomes in Patients with Neovascular AMD Who Exhibited Visual Acuity of 0.1 or Worse at 5th Injection
|
|
Tae Kee-Sun
Kim Jong-Woo
Kim Chul-Gu
Lee Dong-Won
Kim Jae-Hui
|
|
|
Abstract
|
|
|
Purpose: To evaluate one-year follow-up outcomes of patients with neovascular age-related macular degeneration (AMD) who exhibited best-corrected visual acuity (BCVA) of 0.1 or worse at the 5th anti-vascular endothelial growth factor (VEGF) injection. The factors associated with visual prognosis were additionally investigated.
Methods: This retrospective study included 21 eyes (21 patients) diagnosed with neovascular AMD exhibiting BCVA of 0.1 or worse (0.1:13 eyes, worse than 0.1:8 eyes) at the 5th anti-VEGF (VEGF) injection. The timing of the 5th injection was identified. In addition, factors associated with 0.1 or better BCVA at 12 months after the 5th injection were investigated
Results: The timing of the 5th injection was a mean 9.1 ± 3.2 months after diagnosis. The mean logarithm of minimal angle of resolution BCVA at the 5th injection and at 12 months after was 1.14 ± 0.20 and 1.21 ± 0.40, respectively. At 12 months after the 5th injection, 8 eyes (38.1%) and 3 eyes (14.3%) exhibited BCVA of 0.1 and 0.2, respectively. The BCVA at the 5th injection was significantly associated with that measured at 12 months after (p = 0.008).
Conclusions: In eyes exhibiting BCVA of 0.1 or worse at the 5th injection, visual acuity was not significantly changed during 12-months of treatment, and the BCVA at the 5th injection was predictive of the 12-month visual outcome. Visual improvement was noted in some eyes, suggesting the need for continuous treatment for these eyes.
|
|
|
KEYWORD
|
|
|
Aflibercept, Age-related macular degeneration, Anti-vascular endothelial growth factor, Choroidal neovascularization, Ranibizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|